Bio-Reference Laboratories Inc

Bio-Reference Laboratories — Merger or Acquisition (June 2015)

8 slides from Bio-Reference Laboratories's merger presentation, Jun 18, 2015

  1. Slide 1: Exhibit 99.2

    Slide 1: Exhibit 99.2

    June Exhibit 99.2

  2. Slide 2: BioReference Laboratories Snapshot

    Slide 2: BioReference Laboratories Snapshot

    Division Key Products Markets BioReference Laboratories Snapshot Physician Offices, Health Facilities, Correctional Facilities Flow Cytometry, IHC, FISH, ISH, Microarray, Morphology Hematologists, Oncologists, Hospital Pathologists Obstetricians, Gynecologists, Maternal-Fetal Medicine NextGen & Sang

  3. Slide 3: What is the 4Kscore Test?

    Slide 3: What is the 4Kscore Test?

    Components Components Results Results OPKO ALGORITHM What is the 4Kscore Test? + Age, DRE, and prior biopsy status % risk of having aggressive prostate cancer for an individual patient OPKO { 4 kallikrein levels: Total PSA Free PSA Intact PSA hK2

  4. Slide 4

    Slide 4

  5. Slide 5: Prostate cancer screening and biopsy pathway

    Slide 5: Prostate cancer screening and biopsy pathway

    Monitor w PSA or PCA3, ConfirmMDx Monitor w PSA or PCA3, ConfirmMDx 100,000 Standard TRUS or mp MRI-Guided Biopsy 100,000 Standard TRUS or mp MRI-Guided Biopsy Negative Biopsy Histopathology Negative Biopsy Histopathology Biopsy Result Biopsy Result Primary Treatment Surgery / Radiation Primary Trea

  6. Slide 6: 4Kscore pathway: biopsy reduction and savings

    Slide 6: 4Kscore pathway: biopsy reduction and savings

    Monitor w PSA if abnormal, 4Kscore Monitor w PSA if abnormal, 4Kscore Biopsy Result Biopsy Result Primary Treatment Surgery / Radiation Primary Treatment Surgery / Radiation Active Surveillance Active Surveillance Primary Treatment Surgery / Radiation Primary Treatment Surgery / Radiation Negative B

  7. Slide 7: The 4Kscore Test Predicts Metastases Within Years

    Slide 7: The 4Kscore Test Predicts Metastases Within Years

    The 4Kscore Test Predicts Metastases Within years 16% < 2% 4Kscore Test > 7.5% 4Kscore Test 7.5% ¹ Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case–Control Study European Urology (in press)

  8. Slide 8: Claros 1: Rapid Testing in the Physician Office

    Slide 8: Claros 1: Rapid Testing in the Physician Office

    Claros ® 1: Rapid Testing in the Physician Office

Source: SEC EDGAR · 425 filed Jun 18, 2015

More decks from Bio-Reference Laboratories Inc